This article is more than 5 years old. Information may no longer be current.
SFA Therapeutics HBV, HCC therapy candidate expands to NASH
Click Here to Manage Email Alerts
SFA Therapeutics received second patent approval for its liver disease therapy SFA001, according to a press release.
The new patent expands SFA001’s designations from prevention of the progression of hepatitis B and hepatocellular carcinoma to include direct treatment for patients with liver fibrosis, nonalcoholic steatohepatitis, and liver cancer derived from HCC.
SFA001 has been licensed by Temple University to SFA Therapeutics. The therapy targets Ffar2 (GPR43), Ffar3 (GPR441), and down-regulating NF-kB.
“SFA Therapeutics’ microbiome-derived agents represent a ‘game-changing’ new paradigm,” Mark Feitelson, PhD, chair of the professional science master’s program in biotechnology from Temple University, said in the release. “Moreover, these compounds are nontoxic at therapeutic doses, stable, can be taken orally, and will be cost competitive, so that they will be accessible by patients in both developed and developing countries.”
Reference: www.sfatherapeutics.com